GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OmniAb Inc (NAS:OABI) » Definitions » Piotroski F-Score

OmniAb (OmniAb) Piotroski F-Score : 4 (As of May. 10, 2024)


View and export this data going back to 2022. Start your Free Trial

What is OmniAb Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

OmniAb has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for OmniAb's Piotroski F-Score or its related term are showing as below:

OABI' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 4   Max: 4
Current: 4

During the past 5 years, the highest Piotroski F-Score of OmniAb was 4. The lowest was 4. And the median was 4.


OmniAb Piotroski F-Score Historical Data

The historical data trend for OmniAb's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OmniAb Piotroski F-Score Chart

OmniAb Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A N/A N/A 4.00

OmniAb Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A 4.00

Competitive Comparison of OmniAb's Piotroski F-Score

For the Biotechnology subindustry, OmniAb's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OmniAb's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OmniAb's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where OmniAb's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -6.1 + -14.728 + -15.738 + -14.053 = $-50.62 Mil.
Cash Flow from Operations was 27.688 + -10.022 + -6.198 + -9.121 = $2.35 Mil.
Revenue was 16.919 + 6.946 + 5.477 + 4.822 = $34.16 Mil.
Gross Profit was 16.919 + 6.946 + 5.477 + 4.822 = $34.16 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(421.212 + 413.041 + 405.239 + 391.708 + 375.225) / 5 = $401.285 Mil.
Total Assets at the begining of this year (Dec22) was $421.21 Mil.
Long-Term Debt & Capital Lease Obligation was $22.08 Mil.
Total Current Assets was $94.90 Mil.
Total Current Liabilities was $23.12 Mil.
Net Income was -6.282 + -10.276 + -12.596 + 6.82 = $-22.33 Mil.

Revenue was 9.623 + 7.199 + 6.91 + 35.345 = $59.08 Mil.
Gross Profit was 9.623 + 7.199 + 6.91 + 35.345 = $59.08 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(304.465 + 0 + 306.634 + 237.613 + 421.212) / 5 = $317.481 Mil.
Total Assets at the begining of last year (Dec21) was $304.47 Mil.
Long-Term Debt & Capital Lease Obligation was $24.02 Mil.
Total Current Assets was $124.95 Mil.
Total Current Liabilities was $26.02 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

OmniAb's current Net Income (TTM) was -50.62. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

OmniAb's current Cash Flow from Operations (TTM) was 2.35. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-50.619/421.212
=-0.12017464

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-22.334/304.465
=-0.0733549

OmniAb's return on assets of this year was -0.12017464. OmniAb's return on assets of last year was -0.0733549. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

OmniAb's current Net Income (TTM) was -50.62. OmniAb's current Cash Flow from Operations (TTM) was 2.35. ==> 2.35 > -50.62 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=22.075/401.285
=0.05501078

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=24.016/317.481
=0.07564547

OmniAb's gearing of this year was 0.05501078. OmniAb's gearing of last year was 0.07564547. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=94.901/23.116
=4.10542481

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=124.95/26.022
=4.80170625

OmniAb's current ratio of this year was 4.10542481. OmniAb's current ratio of last year was 4.80170625. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

OmniAb's number of shares in issue this year was 100.169. OmniAb's number of shares in issue last year was 115.218. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=34.164/34.164
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=59.077/59.077
=1

OmniAb's gross margin of this year was 1. OmniAb's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=34.164/421.212
=0.0811088

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=59.077/304.465
=0.19403544

OmniAb's asset turnover of this year was 0.0811088. OmniAb's asset turnover of last year was 0.19403544. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+0+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

OmniAb has an F-score of 4 indicating the company's financial situation is typical for a stable company.

OmniAb  (NAS:OABI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


OmniAb Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of OmniAb's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


OmniAb (OmniAb) Business Description

Traded in Other Exchanges
N/A
Address
5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608
OmniAb Inc offers therapeutic antibody discovery technologies. Its focus is to enable the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully-human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Executives
Matthew W Foehr director, officer: President & CEO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Steven Love director C/O OMNIAB, INC., 5980 HORTON STREET, SUITE 600, EMERYVILLE CA 94608
Carolyn R Bertozzi director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
John L Higgins director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Avista Capital Managing Member V, Llc director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V Gp, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners (offshore) V, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V, L.p. director, 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Thompson Dean director, 10 percent owner 65 EAST 55TH STREET, 18TH FLOOR, C/O AVISTA CAPITAL PARTNERS, NEW YORK NY 10022
Avista Acquisition Lp Ii director, 10 percent owner C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Acquisition Gp Llc Ii director, 10 percent owner C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
David F Burgstahler director, 10 percent owner C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Kurt A Gustafson officer: EVP, Finance and CFO 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Sarah Boyce director C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010